Benchmark analyst Bruce Jackson lowered the firm’s price target on Humacyte (HUMA) to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte’s new shares for the target drop but believes the company’s customer base continues to build.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Positive Growth Prospects and Financial Stability Drive Buy Rating for Humacyte
- Humacyte Reports Q3 2025 Financial Results and Pipeline Progress
- Humacyte’s Earnings Call Highlights Growth and Challenges
- Humacyte’s Promising Growth and Strategic Collaborations Earn a Buy Rating
- Humacyte reports Q3 EPS (11c), consensus (15c)